Description: Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Home Page: oculis.com
Bahnhofstrasse 7
Zug,
6300
Switzerland
Phone:
41 41 711 9325
Officers
| Name | Title |
|---|---|
| Dr. Riad Sherif M.B.A., M.D. | CEO & Director |
| Ms. Sylvia Cheung | Chief Financial Officer |
| Ms. Gudrun Bachmann Ph.D. | Chief Technology Officer |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer |
| Mr. Daniel S. Char J.D. | Chief Legal Officer |
| Ms. Virginia R. Dean | Chief Human Resources Officer |
| Mr. Páll Ragnar Jóhannesson | Chief Business Officer |
| Ms. Rebecca Weil | Chief Commercial Officer |
| Dr. Snehal Shah Pharm.D. | President of Research & Development |
| Dr. Sharon Klier M.D., M.P.H. | Chief Development Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.453 |
| Price-to-Sales TTM: | 801.4491 |
| IPO Date: | 2023-03-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 36 |